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ABSTRACT
Objectives: Vitamin D is an immunomodulator and
can alter response to tuberculosis (TB) treatment,
though randomised trials have been inconclusive to
date. We present one of the first comprehensive
analysis of the associations between vitamin D status
and TB treatment, T-cell counts and nutritional
outcomes by HIV status.
Design: Cohort study.
Setting: Outpatient clinics in Tanzania.
Participants: 25-hydroxyvitamin D levels were
assessed in a cohort of 677 patients with TB (344
HIV infected) initiating anti-TB treatment at
enrolment in a multivitamin supplementation
(excluding vitamin D) trial (Clinicaltrials.gov identifier:
NCT00197704).
Primary and secondary outcome measures:
Information on treatment outcomes such as failure and
relapse, HIV disease progression, T-cell counts and
anthropometry was collected routinely, with a median
follow-up of 52 and 30 months for HIV-uninfected and
HIV-infected patients, respectively. Cox and binomial
regression, and generalised estimating equations were
used to assess the association of vitamin D status with
these outcomes.
Results: Mean 25-hydroxyvitamin D concentrations at
enrolment were 69.8 (±21.5) nmol/L (27.9 (±8.6) ng/
mL). Vitamin D insufficiency (<75 nmol/L) was
associated with a 66% higher risk of relapse (95% CI
4% to 164%; 133% higher risk in HIV-uninfected
patients). Each unit higher 25-hydroxyvitamin D levels
at baseline were associated with a decrease of 3
(p=0.004) CD8 and 3 (p=0.01) CD3 T-cells/µL during
follow-up in patients with HIV infection. Vitamin D
insufficiency was also associated with a greater
decrease of body mass index (BMI; –0.21 kg/m2; 95%
CI −0.39 to −0.02), during the first 8 months of
follow-up. No association was observed for
vitamin D status with mortality or HIV disease
progression.
Conclusions: Adequate vitamin D status is associated
with a lower risk of relapse and with improved
nutritional indicators such as BMI in patients with TB,
with or without HIV infection. Further research is
needed to determine the optimal dose of vitamin D and
effectiveness of daily vitamin D supplementation
among patients with TB.
INTRODUCTION
Mycobacterium tuberculosis is one of the most
pernicious infectious diseases and successful
pathogens known to man. More than 95% of
the estimated cases and deaths due to tuber-
culosis (TB) occur in low-income countries.
The United Republic of Tanzania is 1 of the
22 high-burden countries that account for
80% of global TB cases. Tanzania has an inci-
dence of 177 cases/100 000 population/year
and a prevalence of 183 cases/100 000 popu-
lation/year.1
The spread of HIV has fuelled the resur-
gence of the TB epidemic in Tanzania, as in
other parts of sub-Saharan Africa.2 HIV is the
strongest factor in the development of active
TB; it is estimated that only 1 of 10 immuno-
competent persons infected with TB devel-
ops active TB in his/her lifetime; whereas,
1 of 10 HIV-infected persons infected with
TB will develop active TB every year. An esti-
mated 38% of patients with TB in Tanzania
are also infected with HIV.1
Current treatment regimens, given under
appropriate management conditions, are
nearly 100% curative for patients with drug-
susceptible organisms. However, in Tanzania,
treatment fails in 12–17% of the cases.
Strengths and limitations of this study
▪ The major strengths of this study include a large
number of participants, more than half of whom
were HIV-infected, comprehensive assessment of
clinical, immunological, sociodemographic and
nutritional parameters, and a long duration of
follow-up.
▪ On the other hand, the major limitation is the pos-
sibility of reverse causation and residual
confounding.
▪ We have attempted to minimise this through
rigorous analyses and adjusting for several poten-
tial confounders, including haemoglobin concen-
trations, HIV status, viral load, CD4 T-cells and
Karnofsky score, in most analyses.
Mehta S, Mugusi FM, Bosch RJ, et al. BMJ Open 2013;3:e003703. doi:10.1136/bmjopen-2013-003703 1
Open Access Research
Additionally, patients with TB in settings such as
Tanzania grapple with multiple health-related and
quality-of-life issues, which are not addressed adequately
with treatment alone.
Recent data have suggested that optimal vitamin D
status may be associated with a more effective immune
response to TB infection, a faster rate of bacteriological
cure, and better long-term outcomes. For example, a
recent cross-sectional study found that vitamin D deﬁ-
ciency is highly prevalent in South Africa and is asso-
ciated with susceptibility to active TB both in the
presence and absence of HIV infection.3 A few rando-
mised trials have also been conducted; two of the recent
ones failed to ﬁnd an effect of vitamin D supplementa-
tion on treatment success.4 5 However, the dose used
and duration of supplementation may have precluded
ﬁnding an effect. Further, most studies had small sample
sizes and assessed only a limited number of covariates.
In this paper, we comprehensively examined the
hypotheses that vitamin D status may be associated with
response to treatment, risk of treatment failure, labora-
tory parameters such as T-cell counts and anthropomet-
ric measurements in the context of a randomised trial of
micronutrient supplementation (supplement did not
contain vitamin D) in Tanzania to better inform future
studies or trials.
MATERIALS AND METHODS
Study population
The study population and recruitment methods have
been described in detail earlier.6 Brieﬂy, 887 adults with
pulmonary tuberculosis (PTB) were enrolled in a rando-
mised trial (Clinicaltrials.gov identiﬁer: NCT00197704)
to examine the effects of micronutrient supplementation
on TB treatment failure, relapse and mortality. The trial
started in April 2000 in Dar es Salaam, Tanzania and con-
tinued until April 2005. The eligibility criteria for the
study included positive sputum smears for acid-fast bacilli
(AFB), age between 18 and 65 years, Karnofsky perform-
ance score of ≥40%,7 plan to stay in Dar es Salaam for
2 years, not being pregnant, and not having received
anti-TB treatment during the previous 1 year. Consenting
participants were randomly assigned in computer-
generated permuted blocks of 20, stratiﬁed by HIV status,
to receive a daily oral dose of one of two regimens: micro-
nutrients (5000 IU retinol, 20 mg vitamin B1, 20 mg
vitamin B2, 25 mg vitamin B6, 100 mg of niacin, 50 µg
vitamin B12, 500 mg vitamin C, 200 mg vitamin E, 0.8 mg
folic acid and 100 µg selenium) or placebo. These doses
represent between 6 and 10 times the recommended
dietary allowance (RDA) and were being tested at the
time among HIV-infected adults from this setting.8 We
chose multiples of the RDA because previous observa-
tional studies suggested that HIV-infected individuals
need higher dietary intakes of micronutrients to achieve
normal serum concentrations.9 All patients received a
daily combination of rifampicin, isoniazid, pyrazinamide
and ethambutol under direct observation of a health
worker during the ﬁrst 2 months (intensive phase) fol-
lowed by 6 months of self-administered daily isoniazid
and ethambutol, as per the Tanzania National TB and
Leprosy Programme guidelines. None of the patients
with HIV infection received antiretroviral therapy, as
these medications were not routinely available in
Tanzania at the time this trial was conducted.
At the time of randomisation, research nurses col-
lected information on various sociodemographic charac-
teristics including age, education levels, marital status
and socioeconomic status. Anthropometric measure-
ments were also obtained using standardised proce-
dures10 at the randomisation visit as well as during each
monthly follow-up visit. Height was measured to the
nearest 0.1 cm using SECA Bodymeter 206 stadiometers,
weight to the nearest 100 g with SECA 700 balance
beam scales and left mid-upper arm circumference at
the midpoint between the acromion and olecranon to
the nearest 0.1 cm using non-stretchable tailor’s tapes.
Physician visits were scheduled every 3 months. During
these visits, study physicians inquired about the health of
the participant during the preceding period and per-
formed a complete physical examination. The stage of
HIV disease was assessed according to the WHO
system.11
A written informed consent was obtained from all the
study participants.
Laboratory methods
At the time of initiation of anti-TB treatment, HIV status
was assessed among consenting patients using two
sequential ELISAs (Wellcozyme, Murex Biotech;
Enzygnost anti-HIV1/2 Plus, Dade Behring); discrepant
results were resolved by western blot test (Bio-rad,
Genetic Systems). Both pretest and post-test counselling
was provided. A blood sample also was obtained for the
measurement of haemoglobin and albumin concentra-
tions using AcT Diff II haematology analyser (Beckman
Coulter, Miami) and Hitachi 911 analyser (Roche
Diagnostics), respectively. CD4, CD3 and CD8 T-cell
counts were determined using FACScount or FACSCan
systems (Becton Dickinson, California, USA). Viral load
was also determined using the Amplicor HIV-1 monitor
version 1.5 assay (Roche Molecular Systems,
Branchburg, New Jersey, USA).
Assessment of vitamin D status
Serum 25-hydroxyvitamin D (25(OH)D) concentrations
were measured using liquid chromatography-mass spec-
trometry at the Children’s Hospital in Boston only at
enrolment before the initiation of micronutrient supple-
mentation. We deﬁned vitamin D insufﬁciency status as
serum 25(OH)D levels of less than 75 nmol/L and
adequate otherwise. Vitamin D deﬁciency was deﬁned as
serum 25(OH)D levels of less than 50 nmol/L.
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Statistical analysis
We examined the association of vitamin D status with TB
treatment outcomes as well as nutritional, immunological
and clinical end points in the entire cohort and separ-
ately by HIV status at baseline. TB-related endpoints
included treatment failure, early relapse and late relapse.
Treatment failure by 1 month was deﬁned as positive AFB
cultures at 1 month from the initiation of treatment.
Relapses were deemed to have occurred in patients with
positive cultures, among those who had become culture
negative after treatment initiation. Relapses/recurrences
included both endogenous reactivation and exogenous
reinfection, which could not be distinguished in this
study. We calculated the relative risks (RRs) and 95% CIs
for each of these outcomes by vitamin D status using
binomial regression. We used Cox proportional hazards
models to assess the association of vitamin D status with
mortality in all patients and HIV disease progression
from stage 3 to 4 in participants with HIV infection. We
deﬁned the end of follow-up as the date when HIV stage
was last assessed.
We examined the association of vitamin D status
with CD4, CD8 and CD3 T-cell counts, viral load (in
participants with HIV infection), indicators of nutri-
tional status (body mass index (BMI) and albumin
concentrations) and haemoglobin concentrations
using generalised estimating equations. These models
do not require that all patients have the same number
of follow-up assessments or that the follow-up measure-
ments be obtained at exactly the same time points. We
assumed a standard normal distribution for repeated
continuous endpoints (T-cell subsets, log10 viral load,
anthropometry and albumin and haemoglobin con-
centrations) and estimated average differences during
follow-up by vitamin D status. We used an exchange-
able correlation structure to account for within-
participant correlations and adjusted the models for
the follow-up time when the measurements had been
obtained and for the baseline values.
We analysed the data for the entire period and for the
ﬁrst 8 months, coinciding with the expected end of TB
treatment. Multivariate analyses adjusted for age,
Karnofsky score, baseline haemoglobin concentrations,
viral load, HIV status, CD4 T-cell counts and micronu-
trient supplementation, unless otherwise speciﬁed in the
results section or the tables. All analyses were performed
using SAS software V.9.3 (SAS Institute Inc, Cary, North
Carolina, USA).
RESULTS
Baseline 25(OH)D concentrations were available for 677
patients of the original cohort of 887. Mean 25(OH)D
concentration was 69.8 (±21.5) nmol/L (27.9 (±8.6) ng/
mL) and its distribution is shown in ﬁgure 1. The base-
line characteristics of these 677 patients by HIV status
are presented in table 1. Thirty-six per cent of the
patients with HIV infection had CD4 T-cell counts below
200 cells/μL. The mean BMI was 19.1±2.7 kg/m2. The
median follow-up time for patients with without HIV
infection was 52 months (IQR: 47–57 months) and for
patients with HIV infection was 30 months (IQR: 15–
41 months).
The mean 25(OH)D concentrations were signiﬁcantly
different across season of blood draw in this cohort
(p=0.004). Tanzania has four seasons: dry ( January–
February); long rains (March–June); dry ( July–
October); short rains (November–December). The
boxplot of vitamin D’s association with season of blood
draw is presented in ﬁgure 2. In subgroup analyses, this
association was only observed among patients without
HIV infection.
We examined the correlates of vitamin D insufﬁciency,
deﬁned as serum 25(OH)D concentrations below
75 nmol/L (75 nmol/L) in online supplementary tables
S1 (HIV-uninfected) and 2 (HIV-infected). All factors
that had univariate associations with p<0.20 were
included in a multivariate model; only the factors that
had p<0.05 were retained in the ﬁnal model. Among the
HIV-uninfected subset, patients enrolled in the dry
winter season between July and October were 50% more
likely to have vitamin D insufﬁciency, compared with
patients enroled in the dry summer season between
January and February (p value for season=0.002).
Similarly, the participants with the lowest height were
more likely to have vitamin D insufﬁciency (p=0.01).
Finally, greater expenditure on food per person per day
was associated with a lower risk of having inadequate
vitamin D status (RR/1000 Tanzanian Shillings (approxi-
mately 1 US$ at the time of the study): 0.76; 95% CI
0.59 to 0.98). In the HIV-infected subset, patients with
higher haemoglobin concentrations at baseline were less
likely to have vitamin D insufﬁciency, with a 7% lower
risk per 1 g/dL higher haemoglobin level (p=0.007).
On the other hand, higher number of CD4 T-cells was
associated with a higher risk of having inadequate
vitamin D status (4% higher risk per 100 CD4 T-
cells/µL; p=0.02).
Figure 1 Distribution of 25-hydroxyvitamin D concentrations
at baseline (nmol/L).
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There was no signiﬁcant association of vitamin D
status at TB treatment initiation with mortality or HIV
disease progression in this cohort (table 2 includes only
participants with HIV infection as there were only 13
deaths in the HIV-uninfected subset). There was no asso-
ciation observed between vitamin D status and treatment
failure 1 month after initiation of TB treatment
(table 3). However, patients with vitamin D insufﬁciency
(<75 nmol/L) had a 66% higher risk of relapse after
becoming culture-negative at 1 month after initiation of
TB treatment (95% CI 4% to 164%). This association
was more pronounced in those who were not HIV
Table 1 Baseline characteristics of the study population (n=677)
Variable
HIV-infected (n=344) HIV-uninfected (n=333)
Mean (SD) Mean (SD)
Age, years 34.4±8.6 30.2±9.2
Money spent on food per person per day, Tanzanian Shillings* 587.3±445.9 580.1±684.2
Haemoglobin, g/dL 9.9±1.8 11.1±1.7
Albumin, g/dL 2.8±1.0 3.2±1.1
CD3 T-cell count, cells/µL 1228.0±608.5 1195.9±404.8
CD4 T-cell counts, cells/µL 327.2±246.2 709.2±250.8
CD8 T-cell counts, cells/µL 826.9±447.5 427.5±188.2
Log(10) viral load, copies/mL 4.6±1.0 N/A
Body mass index (BMI), kg/m2 19.4±2.8 18.8±2.5
Mid-upper arm circumference, cm 23.4±2.7 23.1±2.7
Follow-up time, days 916.8±507.4 1532.9±331.4
n (%) n (%)
Vitamin D insufficiency (serum 25-hydroxyvitamin D <75 nmol/L) 218 (63.4) 200 (60.1)
Vitamin D deficiency (serum 25-hydroxyvitamin D <50 nmol/L) 55 (16.0) 51 (15.3)
Sex
Male 203 (59.0) 257 (77.2)
Female 141 (41.0) 76 (22.8)
Centre
Mwananyamala 79 (23.0) 88 (26.4)
Temeke 102 (29.7) 83 (24.9)
Tandale 83 (24.1) 91 (27.3)
Mbgala 31 (9.0) 70 (21.0)
Amana 49 (14.2) 1 (0.3)
Karnofsky score <70% 45 (13.1) 29 (8.7)
Education group
None 29 (8.4) 36 (10.8)
Low <5 years 35 (10.2) 31 (9.3)
Primary 5–8 years 238 (69.2) 233 (70.0)
Secondary/university 42 (12.2) 33 (9.9)
Cohabits with a partner 200 (58.1) 168 (50.5)
Assets at home
None 92 (26.9) 108 (32.4)
1 89 (26.0) 85 (25.5)
2–3 122 (35.7) 114 (34.2)
4–5 39 (11.4) 26 (7.8)
WHO HIV disease stage
3 240 (90.9) N/A
4 24 (9.1)
CD4 T-cell categories, cells/µL
0–199 97 (35.9) 0 (0)
200–499 116 (43.0) 69 (22.9)
500+ 57 (21.1) 232 (77.1)
WHO BMI group, kg/m2
<16 26 (7.7) 33 (9.9)
16–16.99 37 (10.9) 45 (13.6)
17–18.49 73 (21.5) 88 (26.5)
18.5–19.99 79 (23.3) 70 (21.1)
20–21.99 77 (22.7) 69 (20.8)
22+ 47 (13.9) 27 (8.1)
*US$1≅1000 Tanzanian Shillings at the time of the study.
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infected at enrolment in the study (RR: 2.33; 95% CI
1.26 to 4.29). In analysis with continuous vitamin D
levels, each nmol/L increase was associated with a 1%
lower risk of relapse during follow-up (p=0.04).
Vitamin D insufﬁciency was observed to have no asso-
ciation with CD4 T-cell counts during the entire
follow-up in either the HIV-infected or the
HIV-uninfected subsets (table 4). However, vitamin D
insufﬁciency was associated with greater CD4 T-cell
counts during the ﬁrst 8 months of follow-up in the
patients with HIV infection (mean difference: 58; 95%
CI 13 to 104).
In analysis among patients with HIV infection with
continuous vitamin D levels, each nmol/L higher
vitamin D concentration was associated with a decrease
of three CD8 and three CD3 T-cells per µL. Vitamin D
insufﬁciency was associated with an average of 85 higher
CD8 T-cells/µL during follow-up (95% CI 4 to 165).
Similar results were observed when we restricted the ana-
lyses to the ﬁrst 8 months of follow-up: the duration of
TB treatment at the time of the study in Tanzania. No
relationship was observed with mean viral loads during
follow-up in the patients who were HIV infected at the
time of enrolment.
In analysis examining association of vitamin D status
with nutritional parameters in the entire period of
follow-up, no signiﬁcant relationship was observed with
BMI, albumin or haemoglobin concentrations (table 5).
During the ﬁrst 8 months of follow-up, patients with
vitamin D insufﬁciency experienced a decline in BMI
(mean: –0.21 kg/m2; 95% CI −0.39 to −0.02), compared
with patients with adequate vitamin D status. These
results were more pronounced in patients without HIV
infection (mean −0.34; 95% CI −0.60 to −0.09) and not
signiﬁcant in patients with HIV infection. Patients with
HIV infection with vitamin D insufﬁciency had increased
albumin levels (mean 0.94; 95% CI 0.55 to 1.32) during
the ﬁrst 8 months of follow-up compared with patients
with adequate vitamin D status.
DISCUSSION
In this study among 677 patients with TB in Tanzania,
more than 61% of the participants had 25(OH)D con-
centrations below 75 nmol/L (30 ng/mL). 25(OH)D
concentrations were associated with the season of blood
draw, money spent on food per person per day, and
height in HIV-uninfected participants and haemoglobin
concentrations and CD4 T-cell counts among patients
with HIV infection. Vitamin D insufﬁciency (<75 nmol/
L) was not associated with mortality, HIV disease pro-
gression or treatment failure during follow-up in the
entire cohort. However, patients with vitamin D insufﬁ-
ciency had an increased risk of experiencing TB relapse
Table 2 Vitamin D status and mortality and HIV disease progression in patients with HIV infection and tuberculosis
Univariate Multivariate
Outcome n/N (%) IRR (95% CI) p Value IRR (95% CI) p Value
Mortality
Vitamin D insufficiency (<75 nmol/L) 61/218 (28.0) 0.73 (0.50 to 1.08) 0.12 0.70 (0.47 to 1.04) 0.08
Adequate vitamin D 43/126 (34.1)
Vitamin D deficient (<50 nmol/L) 20/55 (36.4) 1.34 (0.82 to 2.18) 0.25 0.91 (0.55 1.50) 0.71
Not deficient 84/289 (29.1)
Continuous vitamin D (nmol/L) 1.00 (0.99 to 1.01) 0.49 1.01 (1.00 to 1.02) 0.15
HIV disease progression
Vitamin D insufficiency (<75 nmol/L) 46/150 (30.7) 1.10 (0.67 to 1.82) 0.71 1.08 (0.64 to 1.82) 0.78
Adequate vitamin D 23/90 (25.6) Reference Reference
Vitamin D deficient (<50 nmol/L) 14/34 (41.2) 1.91 (1.05 to 3.44) 0.03 1.48 (0.78 to 2.82) 0.23
Not deficient 55/206 (26.7) Reference Reference
Continuous vitamin D (nmol/L) 0.99 (0.98 to 1.01) 0.30 1. 00 (0.99 to 1.01) 0.57
p Values obtained using Cox proportional hazards regression; IRR, incident rate ratio.
Multivariate analyses adjusted for age, Karnofsky score, baseline haemoglobin, viral load, HIV status, CD4 T-cell counts and micronutrient
supplementation.
Figure 2 Distribution of 25-hydroxyvitamin D concentrations
by season of blood draw; season 1: dry (January–February);
season 2: long rains (March–June); season 3: dry (July–
October); season 4: short rains (November–December).
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during follow-up. Further, vitamin D insufﬁciency was
associated with a decline in CD8 and CD3 T-cells in
both the ﬁrst 8 months (the duration of TB treatment)
and the entire period of follow-up. A similar relationship
was observed with BMI in the ﬁrst 8 months of
follow-up.
Our study was conducted in Dar es Salaam, the largest
urban centre in Tanzania, and just six degrees south of
the Equator. The prevalence of vitamin D insufﬁciency
(>61%) in this study is higher than the approximately
40% found in a previous study among patients with TB
in Mwanza, Tanzania12 and in our studies among
HIV-infected pregnant women (∼85% of them had stage
1 HIV disease, unlike this study) in Dar es Salaam.13 14
However, this prevalence is lower than what was
observed in a cross-sectional study in South Africa,
where 88% of HIV-uninfected and 97% of HIV-infected
patients with TB had vitamin D insufﬁciency. The mean
vitamin D concentration in this study was 69.8 nmol/L,
compared with 86.5 nmol/L in the study in Mwanza and
28.8–40 nmol/L in the South African study. One study
from Thailand observed similar levels (69 nmol/L) in
patients with TB;15 Thailand is located at a similar dis-
tance from the Equator as Tanzania, though it is in the
northern hemisphere. Similar to the study in South
Africa, the vitamin D levels were lowest in our study in
the dry winter season between July and October, though
the differences were not as stark. For example, the mean
vitamin D concentration in January–March in the South
African study was 56.8 and 30.8 nmol/L between July
and September, whereas in our study, the concentrations
were 74.8 nmol/L for January through February, and
66.3 nmol/L for July through October.
Vitamin D is synthesised in the skin through the
action of ultraviolet light on 7-dehydrocholesterol. Fatty
ﬁsh, such as salmon and sardines, are good sources of
vitamin D in the diet but are not widely available every-
where and are usually expensive. Increasing urbanisation
and a tendency to spend most time indoors are major
factors that contribute to the inability of the skin to
synthesise adequate amounts of vitamin D.16–18
Additionally, the TB disease itself and/or the HIV
co-infection in the participants in this study are probably
the primary reasons for restricted physical activity, lack
of adequate exposure to sunlight and consequent low
concentrations of vitamin D.
Several other investigators have examined correlates of
vitamin D status in patients with TB. The study in
Mwanza found that marital status, BMI and serum trans-
ferrin receptor concentrations were correlated with
vitamin D status. Though the ﬁrst two were correlated
with vitamin D status in our study in univariate analyses,
neither remained signiﬁcant in multivariate analyses.
We did not measure serum transferrin receptor in our
study, though we did observe a correlation of vitamin D
status with haemoglobin concentrations among the
HIV-infected subset. Another study in South Africa
found that TB status (active disease vs latent infection),
month of sampling and BMI were signiﬁcantly corre-
lated with vitamin D status in multivariate analyses.3 All
patients in our study had active disease, and we did not
observe a relationship with BMI in our analyses. The
study in South Africa incorporated only those correlates
associated with serum 25(OH)D concentration with
p<0.05 in univariate analysis in the multivariate model.
This may have precluded selection of important covari-
ates and confounders, if measured, and produced
biased estimates and CIs; increasing the nominal signiﬁ-
cance level to 20% or more, as used in this study19 can
eliminate most of this bias. Most other studies have been
with smaller sample sizes and have examined a limited
set of covariates, compared with the current study.
There was no association of vitamin D status with mor-
tality or HIV disease progression in this cohort, unlike
our previous studies among HIV-infected pregnant
women13 20 or adults with HIV infection21 22 in Tanzania.
The major difference is that in our earlier studies,13 20 a
large majority (∼85%) of the participants had stage 1 or
Table 3 Vitamin D status and treatment outcomes in patients with tuberculosis
Univariate Multivariate
Outcome n/N (%) RR (95% CI) p Value RR (95% CI) p Value
Treatment failure by 1-month post-treatment initiation
Vitamin D insufficiency (<75 nmol/L) 58/298 (19.5) 1.06 (0.72 to 1.55) 0.77 1.02 (0.70 to 1.49) 0.93
Adequate vitamin D 34/185 (18.4)
Vitamin D deficient (<50 nmol/L) 15/75 (20.0) 1.06 (0.65 to 1.74) 0.82 1.13 (0.69 to 1.86) 0.63
Not deficient 77/408 (18.9)
Continuous vitamin D (nmol/L) 1.00 (0.99 to 1.01) 0.49 1. 00 (0.99 to 1.01) 0.50
Any relapse (relapse after 1-month post-treatment initiation if culture negative at 1 month)
Vitamin D insufficiency (<75 nmol/L) 51/227 (22.5) 1.56 (0.98 to 2.48) 0.06 1.66 (1.04 to 2.64) 0.03
Adequate vitamin D 21/146 (14.4)
Vitamin D deficient (<50 nmol/L) 13/56 (23.2) 1.25 (0.73 to 2.12) 0.41 1.40 (0.82 to 2.39) 0.21
Not deficient 59/317 (18.6)
Continuous vitamin D (nmol/L) 0.99 (0.98 to 1.00) 0.06 0.99 (0.98 to 1.00) 0.04
p Values obtained using Binomial Regression; RR, risk ratio; multivariate analyses adjusted for age, Karnofsky score, baseline haemoglobin,
viral load, HIV status, CD4 T-cell counts and micronutrient supplementation.
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Table 4 Vitamin D status and T-cell counts (cells/µL) in patients with tuberculosis
Outcome
CD4 T-cells CD8 T-cells CD3 T-cells
Adequate
vitamin D,
mean (SD)*
Vitamin D
insufficiency,
mean difference
(95% CI)†
Vitamin D
insufficiency,
adjusted mean
difference (95%
CI)‡
p
Value
Adequate
vitamin D,
mean (SD)*
Vitamin D
insufficiency,
mean difference
(95% CI)†
Vitamin D
insufficiency,
adjusted mean
difference
(95% CI)‡
p
Value
Adequate
vitamin D,
mean (SD)*
Vitamin D
insufficiency,
mean difference
(95% CI)†
Vitamin D
insufficiency,
adjusted mean
difference (95%
CI)‡
p
Value
Entire follow-up: patients with HIV infection
Vitamin D
insufficiency
(<75 nmol/L)
300 (234) 17 (−23 to 56) 21 (−18 to 59) 0.29 902 (457) 88 (7 to 169) 85 (4 to 165) 0.04 1298 (635) 101 (−4 to 206) 103 (−5 to 212) 0.06
Vitamin D
deficient
(<50 nmol/L)
333 (225) 21 (−34 to 76) 30 (-26 to 86) 0.29 957 (424) 105 (-9 to 219) 114 (-6 to 234) 0.06 1392 (595) 104 (-47 to 255) 125 (-28 to 279) 0.11
Continuous
vitamin D
(per nmol/L)
0 (−1 to 1) -1 (-1 to 0) 0.26 -3 (-5 to -1) -3 (-5 to -1) 0.004 -3 (-5 to -1) -3 (-6 to -1) 0.01
Entire follow-up: patients without HIV infection
Vitamin D
insufficiency
(<75 nmol/L)
771 (235) −2 (−49 to 45) 3 (−45 to 51) 0.91 508 (209) −25 (−63 to 14) −22 (−60 to 17) 0.27 1351 (400) −37 (−109 to 35) −28 (−99 to 44) 0.45
Vitamin D
deficient
(<50 nmol/L)
781 (241) −34 (−99 to 30) −34 (−101 to 32) 0.31 500 (195) −1 (−64 to 62) 3 (−61 to 67) 0.93 1354 (397) −33 (−136 to 71) −28 (−134 to 79) 0.61
Continuous
vitamin D
(per nmol/L)
0 (−1 to 1) 0 (−1 to 1) 0.97 0 (−1 to 1) 0 (−1 to 1) 0.83 0 (−1 to 2) 0 (−2 to 2) 0.90
First 8 months of follow-up: patients with HIV infection
Vitamin D
insufficiency
(<75 nmol/L)
316 (237) 54 (8 to 100) 58 (13 to 104) 0.01 868 (470) 132 (29 to 235) 119 (15 to 223) 0.02 1279 (670) 190 (42 to 337) 179 (28 to 331) 0.02
Vitamin D
deficient
(<50 nmol/L)
372 (264) 36 (−25 to 97) 41 (−20 to 101) 0.19 963 (471) 63 (−77 to 203) 75 (−72 to 221) 0.32 1443 (689) 67 (−125 to 259) 101 (−93 to 295) 0.31
Continuous
vitamin D
(per nmol/L)
−1 (−2 to 0) −1 (−2 to 0) 0.01 −4 (−6 to −1) −4 (−6 to −1) 0.002 −4 (−7 to −1) −5 (−8 to −2) 0.003
First 8 months of follow-up: patients without HIV infection
Vitamin D
insufficiency
(<75 nmol/L)
724 (243) 1 (−52 to 53) 6 (−47 to 59) 0.82 461 (232) −22 (−63 to 20) −17 (−57 to 22) 0.39 1248 (446) −38 (−121 to 46) −27 (−106 to 52) 0.50
Vitamin D
deficient
(<50 nmol/L)
731 (237) −7 (−95 to 80) −7 (−96 to 81) 0.87 454 (209) 4 (−73 to 81) 5 (−71 to 81) 0.90 1247 (410) 14 (−124 to 153) 17 (−123 to 156) 0.82
Continuous
vitamin D
(per nmol/L)
0 (−2 to 1) 0 (−2 to 1) 0.54 0 (−1 to 1) 0 (−1 to 1) 0.73 0 (−2 to 1) 0 (−2 to 1) 0.57
* Data are the means (SD) of the average measurement during follow-up for each participant.
†Data are the mean difference between the low and the adequate vitamin D group. The mean differences, 95% CIs and corresponding p values were estimated from generalised estimating
equations, after adjustment for baseline measurements, follow-up time and treatment (micronutrients vs placebo) group.
‡Multivariate analyses additionally adjusted for age, Karnofsky score and baseline haemoglobin.
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Table 5 Vitamin D status and nutritional parameters in patients with tuberculosis
Outcome
Body mass index (kg/m2) Albumin concentration (g/dL) Haemoglobin concentration (g/dL)
Adequate
vitamin D,
mean (SD)*
Vitamin D
insufficiency,
mean difference
(95% CI)†
Vitamin D
insufficiency,
adjusted mean
difference
(95% CI)‡
p
Value
Adequate
vitamin D,
mean (SD)*
Vitamin D
insufficiency,
mean difference
(95% CI)†
Vitamin D
insufficiency,
adjusted mean
difference
(95% CI)‡
p
Value
Adequate
vitamin D,
mean (SD)*
Vitamin D
insufficiency,
mean difference
(95% CI)†
Vitamin D
insufficiency,
adjusted mean
difference
(95% CI)‡
p
Value
Entire follow-up: all patients
Vitamin D
insufficiency
(<75 nmol/L)
21.20 (2.80) −0.06 (−0.30 to
0.17)
−0.08 (−0.30 to
0.14)
0.46 3.42 (0.74) −0.05 (−0.14 to
0.04)
0.00 (−0.08 to
0.08)
0.97 12.65 (1.80) −0.16 (−0.40 to
0.08)
−0.18 (−0.41 to
0.05)
0.12
Vitamin D
deficient
(<50 nmol/L)
21.23 (3.00) −0.16 (−0.46 to
0.14)
−0.14 (−0.44 to
0.15)
0.34 3.42 (0.72) −0.05 (−0.17 to
0.07)
0.02 (−0.08 to
0.13)
0.65 12.42 (1.87) 0.15 (−0.16 to
0.45)
0.17 (−0.11 to
0.45)
0.24
Continuous
vitamin D
(per nmol/L)
0.00 (0.00 to 0.01) 0.00 (0.00 to 0.01) 0.30 0.002 (0.00 to
0.004)
0.000 (−0.002 to
0.002)
0.90 0.00 (−0.01 to
0.01)
0.00 (0.00 to 0.01) 0.85
First 8 months of follow-up: all patients
Vitamin D
insufficiency
(<75 nmol/L)
20.96 (2.73) −0.20 (−0.40 to
−0.01)
−0.21 (−0.39 to
−0.02)
0.03 3.42 (1.09) −0.01 (−0.18 to
0.16)
0.04 (−0.13 to
0.21)
0.65 12.12 (1.85) −0.01 (−0.28 to
0.26)
−0.04 (−0.31 to
0.23)
0.78
Vitamin D
deficient
(<50 nmol/L)
20.85 (2.84) 0.00 (−0.25 to
0.25)
0.04 (−0.21 to
0.29)
0.78 3.41 (1.08) −0.11 (−0.32 to
0.10)
−0.05 (−0.27 to
0.17)
0.64 11.92 (1.99) 0.16 (−0.18 to
0.50)
0.21 (−0.10 to
0.53)
0.19
Continuous vitamin D (per
nmol/L)
0.00 (0.00 to 0.01) 0.00 (0.00 to 0.01) 0.38 0.000 (−0.003 to
0.005)
0.000 (−0.004 to
0.004)
0.87 0.00 (−0.01 to
0.00)
0.00 (−0.01 to
0.00)
0.57
* Data are the means (SD) of the average measurement during follow-up for each participant.
† Data are the mean difference between the low and the adequate vitamin D group. The mean differences, 95% CIs and corresponding p values were estimated from generalised estimating
equations, after adjustment for baseline measurements, follow-up time and treatment (micronutrients vs placebo) group.
‡Multivariate analyses additionally adjusted for age, Karnofsky score, baseline haemoglobin, viral load, CD4 T cell count and HIV status; HIV status removed from the model where the results
are stratified by HIV status. Viral load also removed from the model in HIV-uninfected individuals.
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asymptomatic HIV disease, whereas in this study, most of
the individuals were already at stage 3 disease.
The association of vitamin D insufﬁciency with TB recur-
rence/relapse, primarily driven by the HIV-uninfected
subset, is a novel ﬁnding in a longitudinal study and has
important implications. Vitamin D deﬁciency has been
linked to TB in several studies—a hypothesis perhaps ini-
tially generated by the observed seasonality of TB. In vitro
and animal studies indicate that 1,25-dihydroxyvitamin D3,
the most active form of vitamin D, may not only increase
mycobacterial killing by macrophages but also limits host
damage by decreasing the γ-interferon production.23–28 In
perhaps the strongest evidence to date for a role of
vitamin D in TB, a study by Liu et al29 found that the anti-
mycobacterial response in humans is dependent on an
adequate availability of vitamin D.
A few randomised trials of vitamin D supplementation
in patients with TB have been conducted in the past few
years.4 5 30 In a randomised trial that was conducted
among 365 patients with TB in Guinea-Bissau starting
antituberculosis treatment, overall mortality was 15% (54
of 365) at 1 year of follow-up and similar in both arms.5
Martineau et al4 did not ﬁnd a difference in median time
to sputum culture conversion with vitamin D supplemen-
tation of 2.5 mg vitamin D3 at enrolment, 14, 28 and
42 days after starting TB treatment in 126 adults with
sputum smear-positive PTB. A recent report by Coussens
et al30 from a subset of the 126 adults included in the trial
above stated that median time to sputum smear conver-
sion in the intervention arm was signiﬁcantly shorter
than in the control arm (23 vs 36 days; p=0.04). The lack
of effect and concordance in most of these trials is prob-
ably due to the dose and dosing interval used. It is worth
noting however, that large intermittent doses of vitamin
D may result in supraphysiological concentrations in
some cases, which may be more harmful than helpful in
their effects on the immune system.31
Vitamin D insufﬁciency also was associated with T-cell
subset counts only among the patients with HIV infec-
tion in this cohort. We can only speculate as to the
reasons for the signiﬁcantly higher increase in CD4
T-cells observed in patients with vitamin D insufﬁciency
at baseline. One potential explanation is that patients
with HIV infection with vitamin D insufﬁciency may
experience more uncontrolled immune reconstitution,
leading to a greater increase in CD4 T-cell counts, on
treatment of TB, compared with patients with adequate
vitamin D status. This may also explain why this relation-
ship is observed only in the ﬁrst 8 months of follow-up
and not subsequently.
The results for CD8 and CD3 T-cells are consistent with
our previous studies among women with HIV infection in
Tanzania.13 14 This could suggest a possible role of
vitamin D in inﬂammation. Although, the conventional
role of CD8 cells is as cytotoxic cells, they also are effector
cells in inﬂammation.32 The involvement of vitamin D in
modulating CD8 cells is also indicated by the fact that
CD8 cells express the highest concentration of vitamin D
receptor of the immune cells.33 Other studies also have
found that vitamin D suppresses antigen-stimulated
proinﬂammatory cytokine responses, which may help
speed up the resolution of inﬂammatory responses that
can lead to increased risk of mortality among patients
with TB.30
TB, once known as ‘consumption’, is associated with
signiﬁcant wasting and weight loss. The observation that
better vitamin D status among patients without HIV
infection is associated with a greater increase in BMI
during follow-up is likely related to decreased risk of
relapse among these patients, as well as improvement in
quality of life through mechanisms such as better metab-
olism that were not directly assessed in this study.
The major strengths of this study include a large
number of participants, more than half of whom were
HIV-infected, comprehensive assessment of clinical,
immunological, sociodemographic and nutritional para-
meters, and a long duration of follow-up. On the other
hand, the major limitation is the possibility of reverse
causation and residual confounding. We have attempted
to minimise this through rigorous analyses and adjusting
for several potential confounders, including haemoglo-
bin concentrations, HIV status, viral load, CD4 T-cells
and Karnofsky score, in most analyses. The study results
are generalisable to most settings with a high TB burden
and widely prevalent vitamin D insufﬁciency.
In summary, our study results indicate that adequate
vitamin D status is associated with better clinical and
nutritional parameters during follow-up in a cohort of
patients with TB in Tanzania. While randomised trials of
vitamin D supplementation among patients with TB are
urgently warranted, it is also imperative to conduct
dose – response studies to determine ideal dose and dur-
ation for the supplement.
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